Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Sep
03
Today In Oncology
MD Anderson President Announces Retirement, Shares Leadership Transition Plans
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma
Sociological Study Explores the Concept of ‘Temporal Misalignment’ Among Patients With Terminal Cancer
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo